Your browser doesn't support javascript.
loading
Reduced-Intensity/Reduced-Toxicity Conditioning Approaches Are Tolerated in XIAP Deficiency but Patients Fare Poorly with Acute GVHD.
Arnold, Danielle E; Nofal, Rofida; Wakefield, Connor; Lehmberg, Kai; Wustrau, Katharina; Albert, Michael H; Morris, Emma C; Heimall, Jennifer R; Bunin, Nancy J; Kumar, Ashish; Jordan, Michael B; Cole, Theresa; Choo, Sharon; Brettig, Tim; Speckmann, Carsten; Ehl, Stephan; Salamonowicz, Malgorzata; Wahlstrom, Justin; Rao, Kanchan; Booth, Claire; Worth, Austen; Marsh, Rebecca A.
Afiliación
  • Arnold DE; Division of Bone Marrow Transplantation and Immune Deficiency, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH, 45229, USA.
  • Nofal R; , CA, San Francisco, USA.
  • Wakefield C; Rush Medical College, Rush University Medical Center, Chicago, IL, USA.
  • Lehmberg K; Division of Pediatric Stem Cell Transplantation and Immunology, University Medical Center Hamburg, Hamburg, Germany.
  • Wustrau K; Division of Pediatric Stem Cell Transplantation and Immunology, University Medical Center Hamburg, Hamburg, Germany.
  • Albert MH; Dr. Von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians University, Munich, Germany.
  • Morris EC; Institute of Immunity and Transplantation, University College London, London, UK.
  • Heimall JR; Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Bunin NJ; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Kumar A; Division of Bone Marrow Transplantation and Immune Deficiency, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH, 45229, USA.
  • Jordan MB; Division of Bone Marrow Transplantation and Immune Deficiency, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH, 45229, USA.
  • Cole T; Department of Allergy and Immunology, The Royal Children's Hospital, Melbourne, VIC, Australia.
  • Choo S; Department of Allergy and Immunology, The Royal Children's Hospital, Melbourne, VIC, Australia.
  • Brettig T; Department of Allergy and Immunology, The Royal Children's Hospital, Melbourne, VIC, Australia.
  • Speckmann C; Institute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Ehl S; Institute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Salamonowicz M; Department of Pediatric Stem Cell Transplantation, Hematology and Oncology, Medical University, Wroclaw, Poland.
  • Wahlstrom J; Blood and Marrow Transplantation Program, Benioff Children's Hospital, University of California San Francisco, San Francisco, CA, USA.
  • Rao K; Department of Bone Marrow Transplantation, Great Ormond Street Hospital for Children, London, UK.
  • Booth C; Department of Pediatric Immunology, Great Ormond Street Hospital, London, UK.
  • Worth A; Department of Pediatric Immunology, Great Ormond Street Hospital, London, UK.
  • Marsh RA; Division of Bone Marrow Transplantation and Immune Deficiency, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH, 45229, USA. Rebecca.Marsh@cchmc.org.
J Clin Immunol ; 42(1): 36-45, 2022 01.
Article en En | MEDLINE | ID: mdl-34586554
ABSTRACT
X-linked inhibitor of apoptosis (XIAP) deficiency is an inherited primary immunodeficiency characterized by chronic inflammasome overactivity and associated with hemophagocytic lymphohistiocytosis (HLH) and inflammatory bowel disease (IBD). Allogeneic hematopoietic cell transplantation (HCT) with fully myeloablative conditioning may be curative but has been associated with poor outcomes. Reports of reduced-intensity conditioning (RIC) and reduced-toxicity conditioning (RTC) regimens suggest these approaches are well tolerated, but outcomes are not well established. Retrospective data were collected from an international cohort of 40 patients with XIAP deficiency who underwent HCT with RIC or RTC. Thirty-three (83%) patients had a history of HLH, and thirteen (33%) patients had IBD. Median age at HCT was 6.5 years. Grafts were from HLA-matched (n = 30, 75%) and HLA-mismatched (n = 10, 25%) donors. There were no cases of primary graft failure. Two (5%) patients experienced secondary graft failure, and three (8%) patients ultimately received a second HCT. Nine (23%) patients developed grade II-IV acute GVHD, and 3 (8%) developed extensive chronic GVHD. The estimated 2-year overall and event-free survival rates were 74% (CI 55-86%) and 64% (CI 46-77%), respectively. Recipient and donor HLA mismatch and grade II-IV acute GVHD were negatively associated with survival on multivariate analysis with hazard ratios of 5.8 (CI 1.5-23.3, p = 0.01) and 8.2 (CI 2.1-32.7, p < 0.01), respectively. These data suggest that XIAP patients tolerate RIC and RTC with survival rates similar to HCT of other genetic HLH disorders. Every effort should be made to prevent acute GVHD in XIAP-deficient patients who undergo allogeneic HCT.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Enfermedades Genéticas Ligadas al Cromosoma X / Enfermedad Injerto contra Huésped / Trastornos Linfoproliferativos Tipo de estudio: Etiology_studies / Observational_studies Límite: Humans Idioma: En Revista: J Clin Immunol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Enfermedades Genéticas Ligadas al Cromosoma X / Enfermedad Injerto contra Huésped / Trastornos Linfoproliferativos Tipo de estudio: Etiology_studies / Observational_studies Límite: Humans Idioma: En Revista: J Clin Immunol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos